

Index

A

acetic acid solution 41–43, 48, 55, 62–64, 70, 78, 79, 82
acetowhitening 62–64, 68, 70, 78, 79, 82, 83, 108
adenocarcinoma 29, 81, 101, 102, 104, 112, 118, 121
adenocarcinoma in situ 81, 101, 102, 104, 133, 134
adenosquamous carcinoma 112
adequacy 9, 45, 48, 52, 56, 59, 77, 140
American Society for Colposcopy and Cervical Pathology (ASCCP) 5, 25
atypical squamous cells of undetermined significance (ASCUS) 2, 5, 8, 97
atypical surface vessels 56, 79–83, 108
atypical transformation zone 20

B

Bethesda system 25
biopsy 8–12, 26, 42, 46–48, 51, 64, 70, 72, 73, 82, 88, 98, 102, 103, 108, 109, 113, 118, 136
blended cutting waveform 92, 95
brachytherapy 123–128
branching surface vessels 61, 63

C

carcinoma in situ 23, 24
cervical glandular intraepithelial neoplasia (CGIN) 101–105
cervical intraepithelial neoplasia (CIN) 1, 2, 7, 11, 20, 23, 24, 26, 27, 31, 32, 56, 59, 60, 79–83, 85–87, 89–92, 97–99, 131–137, 144
cervical stenosis 91, 132
cervicitis 67, 68, 70–73, 140
cervicovaginitis 67, 68, 70–73
chemotherapy 126–128
coagulation waveform 92, 95

coarse mosaic 55, 80, 81, 83, 108
coarse punctation 55, 80, 81, 83, 108
cold-knife conization 87, 91, 98, 118, 120
colposcope 8, 37–39, 45, 46, 48, 145
colposcopic terminology/nomenclature 51–53, 55, 56
colposcopy record/documentation 48, 77, 78, 85
columnar epithelium 14–19, 25, 59–62, 64, 80
concurrent chemoradiotherapy (CCRT) 126–128
condyloma 56, 79, 82
congenital transformation zone 20, 21, 56, 59, 64, 82
consent 47
contraception 25, 61, 136
cryotherapy (cryosurgery, cryo) 87–90, 98
crypts 15–18, 55, 59, 61, 63, 95

D

decontamination 142–145
desiccation 93
dual testing (p16/Ki-67) 5, 32, 34
diskaryosis 4, 5, 24, 26, 27, 101
dysplasia 4, 23–25, 60, 77, 79, 80, 82, 101–104

E

ectocervix 6, 13–17, 19, 20, 26, 48, 52, 53, 59, 64
ectopy 16, 17
ectropion 16, 17, 135
electrosurgical unit (ESU) 39, 92–94, 142, 145
endocervical curettage 14
endocervix 13–17, 19, 41, 48, 51, 52, 56, 59–63, 73, 101–104, 109, 112
excision types 52, 53, 55, 95, 97, 103, 104, 109, 110, 118
external beam radiotherapy (EBRT) 123, 124, 126–128

F

fine mosaic 55, 64, 81, 82
fine punctation 55, 64, 70, 71, 80–82
fulguration 93

G

glandular dysplasia/disease/abnormality 86, 87, 97, 101–105, 134

H

high-grade squamous intraepithelial lesion (HSIL) 1, 5, 10, 26, 27, 31, 32, 63, 79, 80, 82, 97, 101, 108, 133, 135–137
high-level disinfection (HLD) 142–144
histopathology 26
hormone replacement therapy 137
human papillomavirus (HPV) 2, 7, 8, 19, 20, 23–26, 29, 30, 32, 34, 80, 82, 85, 99, 101, 102, 105, 128, 132–134
hyperkeratosis 82
hyperplasia 17, 18, 82
hysterectomy 87, 91, 105, 115, 117, 118, 120, 121, 134, 137

I

IFCPC/IARC training programme 46
immature squamous metaplasia 18, 19, 59, 61–64, 78, 82
inflammatory lesions 67, 68, 70–73, 79
inner border sign 55, 56, 108
instruments 37, 39–43, 46–48, 94, 141–144
International Federation of Cervical Pathology and Colposcopy (IFCPC) 9, 46, 51, 52, 55, 56
International Federation of Gynecology and Obstetrics (FIGO) staging system 107, 110, 113, 116
intracavitary radiotherapy (ICR) 123–128
intrauterine contraceptive device (IUCD) 67, 136, 137

K

keratinizing squamous cell carcinoma 112
koilocytosis 24, 26, 27

L

large loop excision of the transformation zone (LLETZ) 4, 40–43, 53, 55, 86, 87, 91–99, 103, 109, 136
leopard-skin appearance 71
leukoplakia 55, 56, 82
loop electrosurgical excision procedure (LEEP) 4, 40–43, 53, 55, 86, 87, 91–99, 103
low-grade squamous intraepithelial lesion (LSIL) 8, 26, 30, 32, 82, 136
Lugol's iodine solution 14–16, 41, 43, 48, 57, 64, 71

M

mature squamous metaplasia 18, 19, 59, 63
menopause 14, 15, 60–62, 64
microinvasive carcinoma 81, 101, 107–111, 113, 118, 133
molecular biomarkers (E6, E7, E4, MCM) 29–32, 34
Monsel's paste 42, 95

N

nabothian cyst/follicle 18, 55, 59, 61, 63
needle excision of the transformation zone (NETZ) 86
neoadjuvant chemotherapy 127
new squamocolumnar junction 14, 17, 25, 60–62
non-keratinizing squamous cell carcinoma 112

O

Objective Structured Clinical Examination (OSCE) 46
oncogenesis 24, 25
oncogenic (high-risk) HPV 2, 4, 5, 7, 8, 19, 20, 23–25, 29, 30, 32, 34, 105, 131–133
original squamocolumnar junction 13, 16–20, 55, 59–61

P

polyps 15, 16, 56, 57, 61, 63, 64, 72
pregnancy 14, 16, 62, 86, 90, 92, 95–97, 121, 135, 136, 140
proliferative HPV infection 27, 31

R

radiotherapy 113, 117, 118, 120, 121, 123–129, 133, 134
Reid Colposcopic Index 78
reproductive tract infection 67, 68, 70–73, 110, 111, 140, 141
ridge sign 55, 56, 108

S

saline solution 43, 48, 59–61
Schiller test 14, 64
screening 3–8, 34, 51, 85, 96, 99, 101, 105, 108, 131–136, 139, 140
squamous columnar junction (SCJ) 13, 14, 16–19, 21, 48, 55, 56, 59–62, 79, 82, 97, 102–104, 131
squamous epithelium 13–21, 24, 26, 55, 59–64, 71, 80
squamous metaplasia 17–21, 55, 60, 62, 63, 80
sterilization 141–144
straight wire excision of the transformation zone (SWETZ) 53, 55, 91, 98, 109
stratified, non-keratinizing squamous epithelium 14, 15
strawberry appearance 68, 70–72
Swede score 9, 48, 55, 64, 77, 78, 81, 85, 108

T

thermal coagulation 87, 90, 91, 98, 99
transformation zone (TZ) 3, 4, 6, 9, 14, 18–21, 25, 48, 51–53, 55, 56, 59–61, 64, 70, 78, 82, 85–98, 101, 103, 104, 109, 118, 131, 135–137
transformation zone types (1, 2, and 3) 20, 41, 48, 52, 53, 56, 60, 77, 85–89, 95, 97, 98, 109, 131
transforming HPV infection 24–27, 29, 31, 34, 79

U

umbilication 81
United Kingdom National Health Service (NHS) 4, 25, 99, 105, 131, 139

V

vaginal intraepithelial neoplasia 117, 137
viral proteins (E6, E7) 24, 30, 32
visual inspection with acetic acid (VIA) 2, 5, 6, 48, 55, 62–64, 70, 78, 79, 82
visual inspection with acetic acid using magnification 6
visual inspection with Lugol's iodine (VILI) 6, 14, 48, 64, 71